Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids

NCT06932263 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06932263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06932263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
March 26, 2025
Completion date
February 28, 2028
Enrollment
540 (estimated)
Sites
222

Conditions

As the registry lists them; a condition with its own page is linked.

asthma